• Michael Charlton, Gregory T Everson, Steven L Flamm, Princy Kumar, Charles Landis, Robert S Brown, Michael W Fried, Norah A Terrault, Jacqueline G O'Leary, Hugo E Vargas, Alexander Kuo, Eugene Schiff, Mark S Sulkowski, Richard Gilroy, Kymberly D Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M Korenblat, Andrew J Muir, Lewis Teperman, Robert J Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S Pang, John G McHutchison, K Rajender Reddy, Nezam Afdhal, and SOLAR-1 Investigators.
• Division of Hepatology and Liver Transplantation, Intermountain Medical Center, Salt Lake City, Utah. Electronic address: michael.charlton@imail.org.
• Gastroenterology. 2015 Sep 1; 149 (3): 649-59.

Background & AimsThere are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.MethodsIn this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin in patients infected with HCV genotypes 1 or 4. Cohort A enrolled patients with cirrhosis and moderate or severe hepatic impairment who had not undergone liver transplantation. Cohort B enrolled patients who had undergone liver transplantation: those without cirrhosis; those with cirrhosis and mild, moderate, or severe hepatic impairment; and those with fibrosing cholestatic hepatitis. Patients were assigned randomly (1:1) to receive 12 or 24 weeks of a fixed-dose combination tablet containing ledipasvir and sofosbuvir, once daily, plus ribavirin. The primary end point was sustained virologic response at 12 weeks after the end of treatment (SVR12).ResultsWe enrolled 337 patients, 332 (99%) with HCV genotype 1 infection and 5 (1%) with HCV genotype 4 infection. In cohort A (nontransplant), SVR12 was achieved by 86%-89% of patients. In cohort B (transplant recipients), SVR12 was achieved by 96%-98% of patients without cirrhosis or with compensated cirrhosis, by 85%-88% of patients with moderate hepatic impairment, by 60%-75% of patients with severe hepatic impairment, and by all 6 patients with fibrosing cholestatic hepatitis. Response rates in the 12- and 24-week groups were similar. Thirteen patients (4%) discontinued the ledipasvir and sofosbuvir combination prematurely because of adverse events; 10 patients died, mainly from complications related to hepatic decompensation.ConclusionThe combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation. ClinTrials.gov: NCT01938430.Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

53 keywords...

hide…